ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Discovery of Antimicrobial Lysins from the "Dark Matter" of Uncharacterized Phages Using Artificial Intelligence.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Precision phage therapy in the AI/ML era: a systematic review of discovery-to-clinical translation evidence.Frontiers in microbiology · 2026Pooled it
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Exploring the potential of computer simulation models in drug testing and biomedical research: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Harnessing AI for advancing pathogenic microbiology: a bibliometric and topic modeling approach.Frontiers in microbiology · 2024Pooled it
- Climate change impact on disease emergence and antimicrobial resistance: A perspective on transmission and detection.iScience · 2026Review
- Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections.International journal of molecular sciences · 2026Review
- Antibiofilm efficacy of phage W5 against antimicrobial-resistantApplied and environmental microbiology · 2026Article
- Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and Clinical Translation.Antibiotics (Basel, Switzerland) · 2026Review
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- The pangenome: a statistical model, not a fixed biological property.Bioinformatics advances · 2026Review
- Bacteriophage-mediated antibacterial and photodynamic therapies.RSC medicinal chemistry · 2025Review
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- Exploration of the feasibility of clinical application of phage treatment for multidrug-resistantEmerging microbes & infections · 2025Article
- In situ gut microbiota editing: enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages.Nature communications · 2025Article
- Dark Matter Carried byInternational journal of molecular sciences · 2025Article
- Phage and enzyme therapies in wound infections: From lab to bedside.Chinese medical journal · 2025Review
- Advanced Strategies in Phage Research: Innovations, Applications, and Challenges.Microorganisms · 2025Review
- Harnessing advanced computational approaches to design novel antimicrobial peptides against intracellular bacterial infections.Bioactive materials · 2025Article
- Diversity and evolution of prokaryotic viral lytic proteins.The ISME journal · 2025Article
- Optimizing phage therapy with artificial intelligence: a perspective.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The rapid rise of antibiotic resistance and slow discovery of new antibiotics have threatened global health. While novel phage lysins have emerged as potential antibacterial agents, experimental screening methods for novel lysins pose significant challenges due to the enormous workload. Here, the first unified software package, namely DeepLysin, is developed to employ artificial intelligence for mining the vast genome reservoirs ("dark matter") for novel antibacterial phage lysins. Putative lysins are computationally screened from uncharacterized Staphylococcus aureus phages and 17 novel lysins are randomly selected for experimental validation. Seven candidates exhibit excellent in vitro antibacterial activity, with LLysSA9 exceeding that of the best-in-class alternative. The efficacy of LLysSA9 is further demonstrated in mouse bloodstream and wound infection models. Therefore, this study demonstrates the potential of integrating computational and experimental approaches to expedite the discovery of new antibacterial proteins for combating increasing antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.